https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(99)80008-7.pdf

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

OBJECTIVE
Assays for drug resistance testing in human immunodeficiency virus type 1 (HIV-1) infection are now available and clinical studies suggest that viral drug resistance is correlated with poor virologic response to new therapy. The International AIDS Society-USA sought to update prior recommendations to provide guidance for clinicians regarding indications for HIV-1 resistance testing.


PARTICIPANTS
An International AIDS Society-USA 13-member physician panel with expertise in basic science, clinical research, and patient care involving HIV resistance to antiretroviral drugs was reconvened to provide recommendations for the clinical use of drug resistance testing.


EVIDENCE AND CONSENSUS PROCESS
The full panel met regularly between January and October 1999. Resistance and resistance testing data appearing in the last decade through April 2000 and presentations at national and international research conferences were reviewed. Recommendations and considerations were developed by 100% group consensus, acknowledging that definitive data to support final recommendations are not yet available.


CONCLUSIONS
Emerging data indicate that despite limitations, resistance testing should be incorporated into patient management in some settings. Resistance testing is recommended to help guide the choice of new regimens after treatment failure and for guiding therapy for pregnant women. It should be considered in treatment-naive patients with established infection, but cannot be firmly recommended in this setting. Testing also should be considered prior to initiating therapy in patients with acute HIV infection, although therapy should not be delayed pending the results. Expert interpretation is recommended given the complexity of results and assay limitations.

/pdf/antiretroviral-drug-resistance-testing-in-adult-hiv-1-hqzfq27dpk.pdf

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection

https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(98)10411-7.pdf

Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial

ObjectiveAssays for drug resistance testing in human immunodeficiency virus type
1 (HIV-1) infection are now available and clinical studies suggest that viral
drug resistance is correlated with poor virologic response to new therapy.
The International AIDS Society–USA sought to update prior recommendations
to provide guidance for clinicians regarding indications for HIV-1 resistance
testing.ParticipantsAn International AIDS Society–USA 13-member physician panel with
expertise in basic science, clinical research, and patient care involving
HIV resistance to antiretroviral drugs was reconvened to provide recommendations
for the clinical use of drug resistance testing.Evidence and Consensus ProcessThe full panel met regularly between January and October 1999. Resistance
and resistance testing data appearing in the last decade through April 2000
and presentations at national and international research conferences were
reviewed. Recommendations and considerations were developed by 100% group
consensus, acknowledging that definitive data to support final recommendations
are not yet available.ConclusionsEmerging data indicate that despite limitations, resistance testing
should be incorporated into patient management in some settings. Resistance
testing is recommended to help guide the choice of new regimens after treatment
failure and for guiding therapy for pregnant women. It should be considered
in treatment-naive patients with established infection, but cannot be firmly
recommended in this setting. Testing also should be considered prior to initiating
therapy in patients with acute HIV infection, although therapy should not
be delayed pending the results. Expert interpretation is recommended given
the complexity of results and assay limitations.

Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel

Background To evaluate the relation between elective cesarean section and vertical transmission of human immunodeficiency virus type 1 (HIV-1), we performed a meta-analysis using data on individual patients from 15 prospective cohort studies. Methods North American and European studies of at least 100 mother-child pairs were included in the meta-analysis. Uniform definitions of modes of delivery were used. Elective cesarean sections were defined as those performed before onset of labor and rupture of membranes. Multivariate logistic-regression analysis was used to adjust for other factors known to be associated with vertical transmission. Results The primary analysis included data on 8533 mother-child pairs. After adjustment for receipt of antiretroviral therapy, maternal stage of disease, and infant birth weight, the likelihood of vertical transmission of HIV-1 was decreased by approximately 50 percent with elective cesarean section, as compared with other modes of delivery (adjusted odds ratio, 0.43; 95 percent confidence interval, 0.33 to 0.56). The results were similar when the study population was limited to those with rupture of membranes shortly before delivery. The likelihood of transmission was reduced by approximately 87 percent with both elective cesarean section and receipt of antiretroviral therapy during the prenatal, intrapartum, and neonatal periods, as compared with other modes of delivery and the absence of therapy (adjusted odds ratio, 0.13; 95 percent confidence interval, 0.09 to 0.19). Among mother-child pairs receiving antiretroviral therapy during the prenatal, intrapartum, and neonatal periods, rates of vertical transmission were 2.0 percent among the 196 mothers who underwent elective cesarean section and 7.3 percent among the 1255 mothers with other modes of delivery. Conclusions The results of this meta-analysis suggest that elective cesarean section reduces the risk of transmission of HIV-1 from mother to child independently of the effects of treatment with zidovudine.

/pdf/the-mode-of-delivery-and-the-risk-of-vertical-transmission-b9p010t43x.pdf

The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies.

SUMMARY These recommendations update the 1994 guidelines developed by the Public Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal human immunodeficiency virus type 1 (HIV-1) transmission. This report provides health care providers with information for discussion with HIV-1 infected pregnant women to enable such women to make an informed decision regarding the use of antiretroviral drugs during pregnancy. Various circumstances that commonly occur in clinical practice are presented as scenarios and the factors influencing treatment considerations are highlighted in this report. It is recognized that strategies to prevent perinatal transmission and concepts related to management of HIV disease in pregnant women are rapidly evolving. The Perinatal HIV Guidelines Working Group will review new data on an ongoing basis and provide

U.S. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States

Elizabeth Glaser

Papers

U.S. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States